Abstracts tagged "Biologicals"

Abstract Number: 2410 • ACR Convergence 2023
Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients
Luca Quartuccio Quartuccio¹, Elena Treppo², Maria De Martino³, Maria Pillon¹, Simone Perniola⁴, Dario Bruno⁴, Miriam Isola³ and Elisa Gremese⁴, ¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²Physician, Moimacco, Italy, ³Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy, ⁴Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy
Background/Purpose: Glucocorticoids (GCs) are still the mainstay of treatment of Giant Cell Arteritis (GCA). Although GCs are highly effective in GCA, it is well documented…
Abstract Number: 032 • 2023 Pediatric Rheumatology Symposium
From Bedside to Bench and Back: Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes with Hearing Loss as the Primary Presentation, Responsive to Anti-IL1 Therapy
Merav Birk-Bachar¹, Hadar Cohen², Yoel Levinsky³, rotem tal⁴, Gil Amarilyo⁵, Meirav Sokolov⁶, Efrat Sofrin-Drucker⁷, Naama Orenstein⁷, Gabriel Lidzbarsky⁷, Liora Kornreich⁸, Eyal Raveh⁶, Nesya Kropach-Gilad⁷, Motti Gerlic² and Liora Harel⁹, ¹Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ²Sackler Faculty of Medicine, Immunology Department, Tel Aviv University, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁴Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁵Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁶Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁷Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel, ⁸Pediatric Imaging Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel
Background/Purpose: Cryopyrin-associated periodic syndromes (CAPS) are a spectrum of rare autoinflammatory diseases caused by gain-of-function mutations inthe NLRP3 gene. These mutations cause inflammasome hyperactivity and…
Abstract Number: 073 • 2023 Pediatric Rheumatology Symposium
Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy
Claire Yang¹, Natalie Rosenwasser², Xing Wang², Zheng Xu², Joshua Scheck², Ramesh Iyer³ and Yongdong (Dan) Zhao³, ¹University of Washington School of Medicine, Seattle, WA, ²Seattle Children's Hospital, seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disease requiring immunosuppressive therapy in half of patients. Monoclonal Tumor Necrosis Factor inhibitors (TNFi) are…
Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium
Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Ana Isabel Rebollo-Giménez¹, Luca Carlini², Yulia Vyzhga³, Silvia Rosina⁴, Ekaterina Alexeeva⁵, Charlotte Myrup⁶, Silvia Magni Manzoni⁷, Maria Trachana⁸, Valda Stanevicha⁹, Constantin Ailioaie¹⁰, Elena Tsitsami¹¹, Alexis-Virgil Cochino¹², Chiara Pallotti¹³, Silvia Scala¹³, Angela Pistorio¹⁴, Sebastiaan Vastert¹⁵, Joost F. Swart¹⁶ and Nicolino Ruperto¹⁷, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattia Infiammatorie, Genova, Italy, ⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Federal State Autonomous Institution “National Medical Research Center of Children's Health”, Ministry of Health of the Russian Federation, Moscow, Russia, ⁶Rigshospitalet, Pediatric rheumatology unit 4272, Copenhagem, Denmark, ⁷IRCCS Ospedale Pediatrico Bambino Gesù, Division of Rheumatology, Roma, Italy, ⁸Hippokration General Hospital, Thessaloniki University School of Medicine, First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Thessaloniki, Greece, ⁹Riga Stradins University, Children University Hospital, Riga, Latvia, ¹⁰Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ¹¹Aghia Sophia Childrens Hospital, First Department of Pediatrics, University of Athens Medical School, Athens, Greece, ¹²Institute for Mother and Child Care, Pediatrics, Bucharest, Romania, ¹³IRCCS Istituto Giannina Gaslini, U.O.C. Pediatric and Rheumatology Clinic, PRINTO, Genova, Italy, ¹⁴IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ¹⁵Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁶Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, Netherlands, ¹⁷IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, PRINTO, Genova, Italy
Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…
Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Alysha Taxter¹, Marc Natter², Min-Lee Chang², Laura Schanberg³, Valarie Morrow⁴, Eveline Wu⁵, Tedryl Bumpass⁴, Alex Fist⁴, Meg Waite⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁷ and CARRA Registry Investigators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Boston Children's Hospital, Boston, MA, ⁷CARRA, Washington, DC
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
Abstract Number: L07 • ACR Convergence 2022
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Di Wu¹, Jing Li¹, Dong Xu¹, Li Wang¹, Jianmin Fang², Dan Ross³ and Fengchun Zhang⁴, ¹Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, ²Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, ³RemeGen Co., San Diego, CA, ⁴Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China
Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
Abstract Number: L12 • ACR Convergence 2022
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
Remco Erkens¹, Rashmi Sinha², Alex Pickering³, Grant Schulert⁴, Alexei Grom⁴, Lars van der Veken¹, Hanneke van Deutekom¹, Jorg Calis¹, Jorg van Loosdregt⁵ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Systemic JIA Foundation, Cincinnati, OH, ³Systemic JIA Foundation, San Francisso, CA, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University Medical Center Utrecht, Wilhelmina Children's Hospital, Zeist, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe subtype of JIA. Recently, interstitial lung disease (SJIA-LD) has been reported as a severe complication of…
Abstract Number: 0146 • ACR Convergence 2022
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
Lara Sánchez-Bilbao¹, Javier Loricera², Santos Castañeda³, Clara Moriano⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa⁹, Paloma Vela-Casampere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesús Carlos Fernández-López¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Julio Sánchez-Martín¹, Mónica Calderón-Goercke¹, José Luis Hernández¹, Miguel Ángel González-Gay¹⁹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…
Abstract Number: 0315 • ACR Convergence 2022
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Evgeny Nasonov¹, Eugen Feist², Michael Luggen³, Sergey Yakushin⁴, Daria Bukhanova⁵, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁵ and Josef Smolen⁷, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ³University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Ryazan State Medical University named after academician I.P. Pavlov, Ryazan, Russia, ⁵R-Pharm JSC, Moscow, Russia, ⁶R-Pharm, Moscow, Russia, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…
Abstract Number: 0426 • ACR Convergence 2022
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
Jesus Diaz¹, Guillermo Quiceno², Cathy Lee Ching³ and Adela Castro⁴, ¹Hamilton Medical Center, Chattanooga, TN, ²UT Southwestern Medical Center, Dallas, TX, ³University of Mississippi Medical Center, Jackson, MS, ⁴Hamilton Physician Group-Specialty Care, Dalton, GA
Background/Purpose: There is an unmet medical need for the treatment of patients with active ankylosing spondylitis (AS) who have an inadequate response to NSAIDs. Prior…
Abstract Number: 0763 • ACR Convergence 2022
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Vibeke Strand¹, Shaun Bender² and Dorothy McCabe³, ¹Stanford University School of Medicine, Stanford, CA, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severely active…
Abstract Number: 0864 • ACR Convergence 2022
Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Esraa Eloseily¹, Min-Lee Chang², MaryEllen Riordan³, Alan Russell⁴, Marc Natter², Yukiko Kimura⁵ and Grant Schulert⁶, ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Boston Children's Hospital, Boston, MA, ³Hackensack Meridian Health, Hackensack, NJ, ⁴Duke Clinical Research Institute, Duke, NC, ⁵Hackensack Meridian Health, New York, NY, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life threatening clinical problem, and currently affects as many as 1…
Abstract Number: 1035 • ACR Convergence 2022
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Philip J Mease¹, William Tillett², Sarah Ohrndorf³, Michelle Perate⁴, Mary Medysky⁵, Miriam Zimmermann⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Paul Bird⁹, Alen Zabotti¹⁰, Atul Deodhar¹¹ and Dafna Gladman¹², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Seattle, WA, ⁶Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹University of New South Wales, Sydney, Australia, ¹⁰Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ¹²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Gulnara Mamyrova¹, William Nguyen², Hassan Awal¹, Derek Jones¹, Alison Ehrlich³, Kathleen Brindle⁴, Shahriar Haji-Momenian⁴, Robert Sheets⁵, Adeline Y. Chin⁶, Shajia Lu⁷, Massimo Gadina⁷, Hanna Kim⁸, Olcay Y. Jones⁹, Lisa G Rider¹⁰ and Rodolfo V Curiel¹, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, ³Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Radiology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA, ⁶Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁷Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁰Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.